MedTrace Logo

Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

NCT00172380 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2012-12-20

No results posted yet for this study

Summary

To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.

Conditions

Interventions

DRUG

Docetaxel Plus CDDP

docetaxel 36mg/m2 and cisplatin 75mg/m2

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Chong-Jen Yu, M.D,Ph.D. · Department of Internal Medicine, National Taiwan University hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2010-01-31
Completion
2010-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00172380 on ClinicalTrials.gov